SciBase Holding AB (“SciBase”) (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that they have entered into a collaboration agreement […]
BioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”) today announced that it has entered into a new share repurchase program (the “Program”), pursuant to which the […]
Bayer expands global clinical program for darolutamide in prostate cancer Phase III study ARASTEP initiated in hormone-sensitive prostate cancer, in patients with high-risk biochemical […]
Biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) approved for seven indications of reference medicine Humira®* With this approval, Sandoz adalimumab HCF biosimilar will offer US patients […]
Quote Professor Ralf Tönjes Video Player Intensive research is being carried out to enable the transplantation of organs from specially bred pigs to humans. However, […]
Additional indication based on data from the pivotal Phase III ARASENS trial The Chinese National Medical Products Administration (NMPA) has approved the oral androgen receptor […]
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new long-term data for Evrysdi® (risdiplam) in a broad range of people aged 2-25 years with spinal […]
Novartis today presented new data which underscore the transformational and sustained benefit of Zolgensma® (onasemnogene abeparvovec), an essential one-time gene therapy for the treatment of spinal […]
Ready-to-use AgPowered Services from Bayer running on the new Microsoft Azure Data Manager for Agriculture / Readymade capabilities and robust digital infrastructure allow innovators to […]
BioNTech SE (Nasdaq: BNTX, “BioNTech”) reached the next milestone in the establishment of scalable mRNA vaccine production in Africa. The six ISO-sized shipping containers for […]
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the full year and fourth quarter 2022 on Monday, March 27th, […]
Novartis shareholders today agreed to the Board of Directors’ recommendations for all proposed resolutions at the Group’s Annual General Meeting (AGM). A total of 1507 […]
Cross-section of organ-on-chip biochip cavities with cells representing intestinal model. A first-of-its-kind collaboration in the consumer health industry is developing a platform aimed at reducing […]
BioNTech SE (Nasdaq: BNTX, “BioNTech”, “the Company”) announced that the Company and the Weizmann Institute of Science (“Weizmann Institute”) signed a Memorandum of Understanding (MoU). […]
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization […]
Copyright © 2023 | WordPress Theme by MH Themes
